Kevellyn Silveira Gomes Martins

Mrs. Kevellyn Silveira Gomes Martins

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Kevellyn Silveira Gomes MartinsKevellyn Silveira Gomes Martins
Kevellyn Silveira Gomes Martins
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
RMReiner Silveira de Moraes
Reiner Silveira de Moraes
PGPriscylla Tatiana Chalfun Guimaraes-Okamoto
Priscylla Tatiana Chalfun Guimaraes-Okamoto
MFMARCOS FERRANTE
MARCOS FERRANTE
Background/Objectives: The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model to predict gentamicin therapeutic protocols for dogs with varying degrees of renal function impairment, considering the minimum inhibitory concentrations (MICs) of the infecting bacteria. Methods: The PBPK model was built using PK-Sim® software (OPEN SYSTEMS PHARMACOLOGY), based on pharmacokinetic data available in the literature and information on the physicochemical properties of the drug. Model evaluation included the calculation of the geometric mean fold error (GMFE), weighted and percentage residuals were calculated, as well as the following measures: AFE, AWRi, MWRi, MAWRi, APE%, MPE%, MAPE%, MdPE%, and MdAPE%. Therapeutic efficacy was assessed according to the Probability of Target Attainment (PTA), considering an MIC distribution of 0.25 to 8 μg/mL for different doses (2, 4, 6, 8, and 10 mg/kg) using the PK/PD indices Cmax/MIC ≥ 10, AUC/MIC ≥ 50, and AUC/MIC ≥ 110. To compare the pharmacokinetics of gentamicin between healthy dogs and those with decreased renal function, different GFR values corresponding to stages of renal impairment were used, as determined by clinical biomarkers (microalbuminuria, UPC ≥ 2, sCr ≥ 1.2 mg/dL, sCr ≥ 2.4 mg/dL, and sCr ≥ 5 mg/dL). The risk of toxicity was assessed according to AUC24h ≥ 700 mg·h/L and Cmin ≥ 0.5. Results: The model demonstrated good predictive performance, with a GMFE value of 1.13 meeting the double error criterion, and weighted residuals randomly distributed around 0 (p = 0.3792). Through the calculation of PTA, it was observed that efficacy varied according to the PK/PD index used, but values greater than 90% were obtained for MICs up to 4 μg/mL. The model allowed the estimation of protocols for each stage of renal impairment, considering the GFR of each group and the risk of nephrotoxicity, in association with the optimal dose to ensure therapeutic efficacy. Conclusions: These findings make it possible to propose a dose for the treatment of an infection, considering the MIC and the patient’s GFR stage, thereby reducing the risk of adverse effects without compromising treatment efficacy.

27 February 2026 in Semina: Ciências Agrárias
Verified
Journal Article
Open access
PDF file
Kevellyn Silveira Gomes MartinsKevellyn Silveira Gomes Martins
Kevellyn Silveira Gomes Martins
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
KVKarina Krauss Ferraz Vasconcelos
Karina Krauss Ferraz Vasconcelos
DDDiego Díaz
Diego Díaz
NWNelsa Widerhon
Nelsa Widerhon
This study used population pharmacokinetic (popPK) modeling to predict therapeutic efficacy and assess nephrotoxicity risk associated with gentamicin administration in dogs. The model was developed in Monolix 2024 R1 (Lixoft SAS, Simulations Plus Company) using plasma concentrationtime data obtained from the literature. Monte Carlo simulations were subsequently performed in Simulx 2024 (Lixoft SAS, Simulations Plus Company) for gentamicin doses of 2, 4, 6, and 8 mg kg-1 to evaluate therapeutic target attainment and exposure associated with nephrotoxicity risk. The model that best described the observed data was a two-compartment model with linear elimination. Predicted therapeutic efficacy was assessed using the Probability of Target Attainment (PTA) based on the PK/PD target fCmax/MIC ≥ 10 across a range of minimum inhibitory concentrations (MICs). Nephrotoxicity risk was evaluated according to the duration for which plasma gentamicin concentrations remained above the primary nephrotoxicity-risk threshold of 2 μg mL-1. The 8 mg kg-1 regimen achieved PTA values ≥ 90% for pathogens with MIC ≤ 2.0 μg mL-1 and represented the highest-performing simulated regimen among those evaluated. For this regimen, the mean time above the 2 μg mL-1 nephrotoxicity-risk threshold ranged from 4 to 8 hours. These findings support the use of gentamicin against pathogens with MICs ≤ 2 μg mL-1 when administered using extended dosing intervals. However, dose and interval adjustments may be required in critically ill patients. Overall, the popPK approach provides a useful framework for precision dosing, supporting improved predicted efficacy and safety across different dosing regimens.